Dana-Farber Cancer Institute Boston, Massachusetts
Professor of Medicine Harvard Medical School Chief and Director, Division of Gynecologic Oncology
Developing new therapeutic strategies for breast and gynecologic cancers.
There is significant unmet therapeutic need for the two most common gynecologic cancers in the United States, ovarian and endometrial, have genetic overlap with certain types of breast cancer driven by mutations in the BRCA genes. Breast cancer survivors are at risk for these cancers because of inherited high-risk BRCA mutations, rising incidence of endometrial cancer in the United States, and increased risk of endometrial cancer caused by certain breast cancer treatments such as tamoxifen. Poly (ADP-ribose) polymerase (PARP) inhibitors, which target the underlying DNA repair problem, are not beneficial to all patients or the cancer will eventually become resistant to the treatment. Drs. Konstantinopoulos and Matulonis are developing combination therapies that may act synergistically to provide better treatment outcomes for patients with breast or ovarian cancers.
Drs. Konstantinopoulos and Matulonis have multiple clinical trials in progress testing new treatment strategies. During the past year, the trials have yielded several new findings. A phase II study evaluating treatment with the PARP inhibitor talazoparib in combination with immunotherapy avelumab in patients with endometrial cancer that is DNA repair-deficient showed an overall response rate of 40 percent. Additionally, the results of a phase II trial led by Dr. Matulonis testing the chemotherapy letrozole combined with the CDK4/6 inhibitor abemaciclib in ER-positive recurrent endometrial cancer led to the addition of this combination to the National Comprehensive Cancer Network endometrial cancer guidelines in 2023.
In the upcoming year, Drs. Konstantinopoulos and Matulonis will continue to develop new therapeutic strategies for the two most common gynecologic cancers in the U.S., ovarian and endometrial cancer, and continue to expand translational platforms to study these cancers. They will focus on designing and opening new trials for ovarian and endometrial cancers and analyzing the outcomes of their ongoing trials.
Ursula A. Matulonis, MD, is Chief and Director of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. She is the first recipient of the Brock-Wilson Family Chair at the Dana-Farber Cancer Institute. She co-leads the ovarian cancer program within the Dana-Farber/Harvard Cancer Center. Her research focuses on developing new targeted therapies for gynecologic malignancies, with a specific interest in ovarian cancer and endometrial cancer.
Dr. Matulonis has led several PARP inhibitor, anti-angiogenic agent, immunotherapy, and combination trials for ovarian cancer in the United States and internationally. Dr. Matulonis serves on the Massachusetts Ovarian Cancer Task Force, the NRG ovarian committee, and the Scientific Advisory Board for the Ovarian Cancer Research Foundation and the Clearity Foundation. She received the Dana-Farber Dennis Thompson Compassionate Care Scholar award, the Lee M. Nadler “Extra Mile” Award, the Clearity Foundation award, and the Zakim Award at Dana-Farber for patient advocacy.
After receiving her MD from Albany Medical College, she completed an internship and residency at the University of Pittsburgh, followed by a medical oncology fellowship at the Dana-Farber Cancer Institute in Boston, MA.
2008
The Play for P.I.N.K. Award in Honor of Laura Lassman and in Memory of Nicholas Lassman
Support research with a legacy gift. Sample, non-binding bequest language:
I give to the Breast Cancer Research Foundation, located in New York, NY, federal tax identification number 13-3727250, ________% of my total estate (or $_____).
Stay in the know with the latest research news, insights, and resources delivered to your inbox.
Follow BCRF on all the major platforms for research news, inspiring stories, and more.
